RP-HPLC estimation of alogliptin and pioglitazone simultaneously in combined tablet dosage forms by Haribabu, B et al.
345
RESEARCH PAPER
Marmara Pharmaceutical Journal 21/2: 345-354, 2017
DOI: 10.12991/marupj.300864
ABSTRACT
A high performance liquid chromatographic method 
was developed to quantify alogliptin and pioglitazone 
simultaneously in bulk and combined tablet dosage form. The 
chromatographic analysis was done on a Zorbax C8 column 
(150 mm x 4.6 mm internal diameter, 5 μm particle size) with 
a mobile phase of 0.1 M ammonium acetate and methanol 
(50:50, v/v) at 1.0 mL/min. The effluents were monitored at 
248 nm and the retention time of alogliptin and pioglitazone 
were 2.883 min and 4.329 min, respectively. Calibration 
curves were linear from 6.25-18.75 μg/mL for alogliptin and 
11.25-33.75 μg/mL for pioglitazone. The LOD and LOQ 
values for alogliptin were 0.047 and 0.157 μg/mL, respectively; 
corresponding values for pioglitazone were 0.085 and 0.284 μg/
mL, respectively. The precision for alogliptin and pioglitazone 
was in the range of 0.094-0.303% and 0.072-0.239%, 
respectively, with corresponding accuracy of 99.450-99.692% 
and 100.184-100.422%. The developed and validated method 
was successfully applied for the simultaneous determination 
of alogliptin and pioglitazone in tablet formulation.
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1. INTRODUCTION
Alogliptin, chemically known as 2-({6-[(3R)-3-
aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl}methyl)benzonitrile (Figure 1), is 
an oral antihyperglycemic of dipeptidyl peptidase 4 inhibitor 
class. It is used in the treatment of type II diabetes milletus 
(1,2). The inhibition of dipeptidyl peptidase 4 by alogliptin 
increases the quantity of active plasma incretins and glucagon 
like peptide 1 that helps in glycemic control (3).
Pioglitazone, an anti-diabetic drug, belongs to the 
thiazolidinedione class of drugs. Chemically it is known as 
5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-
thiazolidine-2,4-dione (Figure 1). Pioglitazone is prescribed 
to improve control of blood glucose level in adults with type 2 
diabetes mellitus (4). Pioglitazone enhances tissue sensitivity 
to insulin by acting as a potent and selective agonist at 
peroxisome proliferator activated gamma receptor in adipose 
tissue, skeletal muscle and liver (5).
With proper diet and exercise, alogliptin and pioglitazone 
combination is used in the management of high blood sugar 
levels caused by type 2 diabetes (6,7). This combination 
was approved by FDA in 2013 (8). The combination of the 
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selected drugs is not official in any pharmacopeia. Therefore, 
it is essential to develop effective analytical method for the 
simultaneous determination of alogliptin and pioglitazone.
UV spectrophotometric methods like first order derivative, 
dual wavelength, second order derivative and area under 
curve methods were described by Raval & Srinivasa (9) and 
Anusha et al. (10) for the simultaneous estimation of alogliptin 
and pioglitazone in bulk and pharmaceutical dosage forms. 
High performance thin layer chromatographic method was 
reported by Komal & Amrita for the simultaneous assay 
of alogliptin and pioglitazone in combined dosage forms 
(11). In HPTLC method, separation was achieved on Merck 
HPTLC aluminum sheets coated with silica gel 60F254, 
with acetonitrile: 1 % ammonium acetate in methanol 
(4.5:5.5 v/v) as mobile phase and densitometric analysis was 
performed at 254 nm. Though the UV spectrophotometric 
methods reported by Raval & Srinivasa (9) and Anusha et 
al. (10) are simple, they are less selective since they involve 
measurements in the UV range where there is a possibility 
of absorbance by the tablet excipients. One of the important 
validation parameter, method robustness, is not reported 
in the UV spectrophotometric methods. The HPTLC 
method described by Komal & Amrita (10) requires costly, 
sophisticated instrumentation and expertise personnel to 
operate. Moreover the HPTLC instrument is not commonly 
available in the developing and under developed countries.
RP-HPLC methods were also applied to the determination of 
the selected drug combination in bulk and pharmaceutical 
dosage forms by Raval & Srinivasa (12), Neelima et al. (13), 
Manzoor et al. (14) and Mokhtar et al. (15). In Raval & 
Srinivasa method, the separation was carried out on an BDS 
hypersil C18 (250 mm × 4.6 mm, 5 µm) analytical column 
using buffer with pH 3.5 and methanol (70:30, v/v) as mobile 
phase at a flow rate of 1.0 mL/min with UV detection at 
271 nm (12). Using a Hypersil BDS C18, (250 x 4.6 mm, 5 
µm) column as stationary phase and a phosphate buffer of 
pH 4.8-acetonitrile (45:55, v/v) as mobile phase, the selected 
drugs combination in pharmaceutical formulations was 
determined by Neelima et al. (13). The detection wavelength 
was set at 215 nm. In Mokhtar et al. method (14), alogliptin 
and pioglitazone was chromatographed on Enable C18 (250 
mm × 4.6 mm, 5 µm) Column with a mobile phase consisting 
of phosphate buffer with pH 3.6-acetonitrile (35:65, v/v) 
pumped at a flow rate of 1.0 mL/min with UV-detection at 
268 nm. Alogliptin and pioglitazone in tablets was assayed 
by Mokhtar et al. (15) by carrying out chromatography on 
an Inertsil ODS-3 (250 mm × 4.6 mm, 5 µm) column using 
a mixture of methanol and phosphate buffer with pH 3.0 
(80:20, v/v) as mobile phase at a flow rate of 1 mL/min with 
UV-detection at 269 nm.
In the present study, a new RP-HPLC method with PDA 
detector was developed for simultaneous determination 
of alogliptin and pioglitazone in bulk and combined tablet 
dosage form. The method validation has been carried out 
according to the International Conference on Harmonization 
guidelines (16). The developed and validated RP-HPLC 
method was successfully applied to combined tablet dosage 
form.
2. MATERIALS AND METHODS
2.1. Reference standard drugs and tablet dosage forms
Alogliptin and pioglitazone reference standard drugs were 
provided by Lara Drugs Private Limited (Telangana, India) 
as gift samples. They are used as received. The tablet dosage 
form, Oseni tablets (strength 25 mg alogliptin and 45 mg 
pioglitazone), manufactured by Takeda pharmaceuticals 
America Inc., Deerfield was purchased from the local 
pharmacy.
Figure 1. Chemical structures of alogliptin and pioglitazone
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2.2. Chemicals and solvents
The HPLC grade methanol was obtained from Merck India 
Ltd., Mumbai, India. Analytical reagent ammonium acetate 
was obtained from Sd. Fine Chemicals Ltd., Mumbai, India. 
Water was obtained using a Milli-Q system.
2.3. Apparatus and HPLC conditions
The Waters Alliance 2695 Module equipped with a 2998 PDA 
detector with Empower 2 software was used in the current 
analysis. The Zorbax C8 column (150 mm x 4.6 mm internal 
diameter, 5 μm particle size) was used. Isocratic mobile phase 
was composed of 0.1 M ammonium acetate and methanol 
(50:50, v/v) with pH 3.5 (adjusted with orthophosphoric acid: 
Sd. Fine Chemicals Ltd., Mumbai). The same mobile phase 
was used as diluent for the preparation of standard solutions 
of alogliptin and pioglitazone. A flow rate of 1.0 mL/min was 
maintained. The eluted compounds were monitored at 248 
nm. The column temperature was maintained at 30±1 oC. An 
injection volume of 10 μL was used.
2.4. Standard solutions
A stock standard solution (alogliptin - 250 µg/mL and 
pioglitazone – 450 µg/mL) was prepared in a 100 mL 
volumetric flask by dissolving 25 mg of alogliptin and 45 mg 
of pioglitazone in a final volume of 100 mL mobile phase. 
Working standard solutions (6.25-18.75 μg/mL for alogliptin 
and 11.25-33.75 μg/mL for pioglitazone) were prepared from 
the above stock solution by appropriate dilution with mobile 
phase.
2.5. Tablet sample solution
Average weight of ten tablets was determined, transferred 
to a clean dry mortar and grinded into fine powder. Tablet 
powder equivalent to 25 mg of alogliptin and 45 mg of 
pioglitazone was then transferred to a 100 mL volumetric 
flask, 30 mL of mobile phase was added and the flask was 
sonicated for 10 min to dissolve the drugs completely. The 
mixture was diluted up to volume with the mobile phase 
to give a solution containing 250 µg/mL and 450 µg/mL 
of alogliptin and pioglitazone, respectively. This solution 
was filtered through 0.45 μm pore size membrane filter. 
Appropriate dilution (12.50 µg/mL of alogliptin and 22.50 
µg/mL of pioglitazone) was prepared in mobile phase for 
analysis.
2.6. Calibration graph
Working standard solutions equivalent to 6.25-18.75 μg/
mL alogliptin and 11.25-33.75 μg/mL pioglitazone were 
prepared by appropriate dilution of the stock standard 
solution with the mobile phase. 10 µL aliquot of each solution 
was injected automatically into the column in triplicate and 
the chromatograms were recorded. The peak areas of the 
drugs were determined. Calibration graph was constructed 
by plotting the mean peak area against drug concentration. 
The concentration of the unknown was calculated from the 
calibration graph or from the regression equation derived 
from the mean peak area-concentration data.
2.7. Estimation of alogliptin and pioglitzone in combined 
tablet dosage form
10 μL of the tablet sample solution was injected into the HPLC 
system in triplicate. The chromatograms were recorded. The 
peak areas were determined. The concentrations of alogliptin 
and pioglitazone in the combined tablet dosage form were 
calculated from the corresponding calibration curves or 
corresponding regression equations.
2.8. Forced degradation
To assess the stability indicating properties of the proposed 
HPLC method, forced degradation studies were performed. 
The tablet sample was subjected to acid, alkali, oxidation, 
thermal and photo degradation
Acid and alkali hydrolysis
Tablet powder equivalent to 25 mg of alogliptin and 45 mg 
of pioglitazone was transferred to a 100 mL volumetric flask. 
The powder was mixed with 10 mL of 0.1 N hydrochloric acid 
(for acid hydrolysis) or 10 mL of 0.1 N sodium hydroxide (for 
alkali hydrolysis). The solutions were subjected to sonication 
for 30 min. The samples were neutralized with an amount 
of acid (for alkali hydrolysis) or base (for acid hydrolysis) 
equivalent to that of the previously added. The flask was 
made up to the volume with mobile phase.
Oxidative degradation
Tablet powder equivalent to 25 mg of alogliptin and 45 mg 
of pioglitazone was transferred to a 100 mL volumetric 
flask. The contents were mixed with 10 mL of 30% hydrogen 
peroxide solution. The reaction mixture was allowed to 
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sonication for 30 min and then the volume of the flask was 
made up to 100 mL with mobile phase.
Thermal and photo degradation
Tablet sample powder (alogliptin-25 mg and pioglitazone-45 
mg) was exposed to 105oC for 30 min in oven (for thermal 
degradation) or subjected to direct sun light for up to 24 hr 
(for photo degradation). After the specified time, the tablet 
powder was cooled and dissolved in 30 mL of mobile phase 
in a 100 mL volumetric flask. The solution thus prepared was 
diluted to volume with the mobile phase.
The degraded sample solutions were appropriately diluted 
with mobile phase to obtain a concentration of 12.50 µg/mL 
(alogliptin) and 22.50 µg/mL (pioglitazone). The solutions 
were filtered through 0.45 μm pore size membrane filter. A 
volume of 10 μL was injected into the HPLC system and the 
chromatograms were recorded.
3. RESULTS AND DISCUSSION
3.1. Method development
The present study was aimed to establish a sensitive, 
robust and reliable RP-HPLC method for the simultaneous 
determination of alogliptin and pioglitazone in combined 
tablet dosage form. During method development, two 
different columns like the Hypersil BDS C18 column (250 
mm x 4.6 mm internal diameter, 5 μm particle size) and 
Zorbax C8 column (150 mm x 4.6 mm internal diameter, 5 
μm particle size) were tried. Better results (good symmetrical 
sharp peak, acceptable tailing factor and resolution) were 
obtained with Zorbax C8 column (150 mm x 4.6 mm internal 
diameter, 5 μm particle size) maintained at a temperature 
of 30±1 oC. Hence, the same column and temperature was 
chosen for analysis.
Various mobile phases (0.1 % Orthophosphoric aicd: Methanol, 
0.1 M NaH2PO4: Methanol, 0.1 M KH2PO4: Methanol and 
0.1 M ammonium acetate: Methanol) with different ratios, 
flow rate and pH were tried and the responses were recorded. 
After a series of experiments, highly symmetrical and sharp 
peaks of alogliptin and pioglitazone with better resolution 
were obtained at pH 3.5 by using 0.1 M ammonium acetate 
and methanol (50:50 (v/v)) as mobile phase at a flow rate of 
1.0 mL/min. The alogliptin and pioglitazone in the selected 
mobile phase have sufficient absorption at 248 nm, which 
was therefore chosen for the analysis. Figure 2 shows a 
typical HPLC chromatogram of alogliptin and pioglitazone 
using the optimized chromatographic conditions.
3.2. Method validation
The developed RP-HPLC method was validated using ICH 
guidelines (16).
System suitability test
In order to determine the satisfactory resolution and 
reproducibility of the method, suitability parameters, 
including % RSD of retention time, % RSD of peak area, USP 
plate count and USP tailing factor, were investigated. In order 
to test the system suitability, standard solution (alogliptin - 
12.50 μg/mL and pioglitazone - 22.50 μg/mL) was injected 
five times into the HPLC system. The results (Table 1) 
demonstrate the method suitability.
Specificity
Specificity was evaluated by comparing the chromatograms 
of mobile phase blank, placebo blank, working standard 
solution (alogliptin 12.50 μg/mL and pioglitazone 22.50 μg/
mL) and tablet sample solution (alogliptin 12.50 μg/mL 
and pioglitazone 22.50 μg/mL). For this purpose, solutions 
of placebo blank, mobile phase blank, working standard 
and tablet sample was injected into the HPLC system. 
The resulting chromatograms are shown in Figure 3. The 
chromatograms of placebo blank, mobile phase, working 
standard and tablet sample did not show any peaks other 
than that of alogliptin and pioglitazone. This confirmed the 
specificity of the method.
Linearity
Plot of the mean peak area against concentration gave the 
linear relationship over the concentration range 6.25-18.75 
μg/mL for alogliptin and 11.25-33.75 μg/mL for pioglitazone. 
Using the regression analysis, the linear equation obtained 
was: y = 15825 x - 554 (R2 = 0.9999) for alogliptin; y = 61574 
x - 471.2 (R2 = 0.9998) for pioglitazone where y is the mean 
peak area, x is concentration in μg/mL and R2 is the regression 
correlation.
Limit of detection (LOD) and limit of quantification (LOQ)
The limits of detection and quantification were calculated 
according to ICH guidelines. The LOD for alogliptin and 
pioglitazone was 0.047 and 0.085 μg/mL, respectively, while 
LOQ was 0.157 and 0.284 μg/mL, respectively.
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Figure 2. Typical HPLC chromatogram of alogliptin and pioglitazone
Figure 3. Chromatogram of (A) Alogliptin and pioglitazone working standard solution (B) Tablet sample solution 
(C) Placebo blank (D) Mobile phase blank
Haribabu et al.
RP-HPLC Estimation of Alogliptin and Pioglitazone Simultaneously in Combined Tablet Dosage Forms Marmara Pharm J 21/2: 345-354, 2017350
Precision and accuracy
The intra-day and inter-day precision and accuracy of the 
method was tested by applying the proposed HPLC method 
for the determination of working standard solution of 
alogliptin and pioglitazone at a concentration of 12.50 μg/
mL and 22.50 μg/mL, respectively. The working standard 
solution was assayed six times on the same day for intra-day 
analysis and on three consecutive days for inter-day analysis. 
The precision and accuracy were expressed as % relative 
standard deviation and % recovery, respectively. The results 
are shown in Tables 2 and 3. The low values of % RSD and 
good % recovery values confirm the satisfactory precision 
and accuracy of the present HPLC method.
Recovery study
The accuracy of the proposed HPLC method was further 
checked by the standard addition method. For this, the 
pre-analyzed sample solution was spiked with known 
concentration of alogliptin and pioglitazone at three different 
concentration levels (50 %, 100 % and 150 %) the percentage 
recovery data (Table 4) show that the proposed method was 
accurate. Common excipients in tablets did not interfere 
with the assay of alogliptin and pioglitazone indicating the 
selectivity of the method.
Table 2. Intra-day precision and accuracy data of the 
proposed HPLC method
Alogliptin Pioglitazone
Peak area Recovery (%) Peak area Recovery (%)
1976730 98.53 1381221 98.83
1972402 98.32 1388479 99.35
1972552 98.32 1380884 98.80
1974805 98.44 1382787 98.94
1979467 98.67 1387533 99.28
1971548 98.27 1386181 99.18
Average 98.43 Average 99.06
RSD (%) 0.152 RSD (%) 0.239
Table 3. Inter-day precision and accuracy data of the 
proposed HPLC method
Alogliptin Pioglitazone
Peak area Recovery (%) Peak area Recovery (%)
Day 1
2026286 101.00 1395606 99.86
2018801 100.63 1393109 99.68
2027031 101.04 1392061 99.60
2020576 100.72 1398160 100.04
2034946 101.44 1393087 99.68
2019810 100.68 1397336 99.98
Average 100.92 Average 99.81
RSD (%) 0.303 RSD (%) 0.180
Day 2
1988214 99.11 1395715 99.87
1988415 99.12 1392458 99.63
1986324 99.01 1390257 99.47
1988251 99.11 1392548 99.64
1984235 98.91 1395482 99.85
1989325 99.16 1392547 99.64
Average 99.07 Average 99.68
RSD (%) 0.094 RSD (%) 0.149
Day 3
1984267 98.91 1395157 99.83
1989315 99.16 1396385 99.91
1988329 99.11 1393652 99.72
1983679 98.88 1395480 99.85
1988367 99.11 1396354 99.91
1989634 99.18 1395365 99.84
Average 99.06 Average 99.84
RSD (%) 0.131 RSD (%) 0.072
Robustness
The method robustness was performed by evaluating 
the influence of small and deliberate changes in HPLC 
conditions on the system suitability parameters of the 
proposed HPLC method. The selected conditions are flow 
rate (±0.1 mL/min) and temperature (±2 oC). Robustness 
was determined with the working standard solution of 
Table 1. System suitability parameters of the proposed HPLC method
Parameters Alogliptin Pioglitazone Recommended limitValue* RSD (%) Value* RSD (%)
Retention time 2.906 0.761 4.361 0.754 RSD ≤2
Peak area 1976065 0.474 1386415 0.864 RSD ≤2
USP resolution - - 10.41 0.686 > 1.5
USP plate count 8997 0.365 13896 0.524 > 2000
USP tailing factor 1.322 0.632 1.186 0.461 ≤ 2
*Average of five values
Haribabu et al.
RP-HPLC Estimation of Alogliptin and Pioglitazone Simultaneously in Combined Tablet Dosage FormsMarmara Pharm J 21/2: 345-354, 2017 351
alogliptin and pioglitazone at a concentration of 12.50 μg/mL 
and 22.50 μg/mL, respectively. The results are summarized 
in Table 5. In all cases, good separations of both alogliptin 
and pioglitazone were achieved and the system suitability 
parameters are well within the acceptable limits, indicating 
that the proposed HPLC method remained robust under the 
optimized conditions.
Stability studies
Forced degradation studies were carried out to elucidate 
the inherent stability characteristics of the aloglitpin and 
pioglitazone. An ideal stability-indicating HPLC method 
is one that measures the analytes and also resolves its 
degradation products. Different stress conditions were 
applied: acid & base hydrolysis, oxidative, thermal and photo 
degradation.
Alogliptin and pioglitazone were found to degrade under all 
the stress conditions employed. Alogliptin was found to be 
more degraded in thermal degradation and pioglitazone in 
oxidative degradation condition applied. Less degradation of 
both the drugs was observed in photolytic degradation. The 
results of forced degradation studies are shown in Table 6. 
Chromatograms obtained under different stress conditions 
are shown in Figure 4. The developed HPLC method could 
effectively resolve the drugs from their degradation products. 
This confirms the stability indicating power of the developed 
HPLC method.
The chromatographic peak purity tool was applied to 
verify the purity of aloglitpin and pioglitazone peaks in all 
cases. This was done by calculating purity angle and purity 
threshold for aloglitpin and pioglitazone peaks. In all cases, 
aloglitpin and pioglitazone peaks were pure since purity angle 
was less than purity threshold. This showed that aloglitpin 
and pioglitazone peaks had no detectable impurity peaks and 
free of co-eluting degradation products.
3.3. Advantages of the proposed method
The details of the reported RP-HPLC methods for the 
simultaneous assay of alogliptin and pioglitzone are 
summarized in Table 7. The proposed RP-HPLC method 
has the advantages of being more sensitive (12-15), more 
precise (12-15) and more accurate (12-15) than the reported 
Table 4. Recovery data of the proposed HPLC method
Spiked level  
(%)
Concentration of alogliptin 
(μg/mL)
Recovery  
(%)
Mean  
(%)
Concentration of 
pioglitazone (μg/mL)
Recovery  
(%)
Mean  
(%)
Added Found Added Found
50
6.178 6.160 99.709
99.692
11.120 11.163 100.385
100.4226.178 6.156 99.652 11.120 11.168 100.433
6.178 6.160 99.714 11.120 11.170 100.448
100
12.375 12.314 99.509
99.450
22.275 22.308 100.150
100.18412.375 12.282 99.246 22.275 22.313 100.169
12.375 12.325 99.596 22.275 22.327 100.232
150
18.534 18.483 99.729
99.626
33.360 33.399 100.116
100.22118.534 18.450 99.547 33.360 33.445 100.255
18.534 18.460 99.601 33.360 33.458 100.291
Table 5. Robustness data of the proposed HPLC method
Parameter Alogliptin PioglitazoneUSP Tailing USP plate count USP resolution USP Tailing USP plate count USP resolution
Flow rate
1.0 + 0.1 mL/min 1.36 9687 - 1.25 15120 10.71
Flow rate
1.0 – 0.1 mL/min 1.40 8369 - 1.28 13455 10.17
Temperature
30 + 5 oC 1.37 9714 - 1.27 15015 10.70
Temperature
30 - 5 oC 1.42 8508 - 1.29 13532 10.23
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Figure 4. Chromatogram of tablet sample (A) Treated with 0.1 N HCl (B) Treated with 0.1 N NaOH (C) Treated with 
30% H2O2 (D) Exposed to 105oC (E) Exposed to sunlight
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Table 6. Results of degradation studies
Stress condition Drug Peak area Degradation  (%)
Assay  
(%)
Purity 
angle
Purity 
threshold
Retention time of 
degradants
Acid
(0.1N HCl)
Alo 1782654 9.82 90.18 0.554 0.659
5.141Pio 1888497 4.46 95.54 0.528 0.667
Base
(0.1 N NaOH)
Alo 1790579 9.41 90.59 0.494 0.658
5.143Pio 1287248 7.19 92.81 0.299 0.437
Oxidation (30% H2O2)
Alo 1791485 9.37 90.63 0.516 0.659
2.540 & 5.131Pio 1283480 7.46 92.54 0.305 0.437
Dry heat (105oC) Alo 1705211 13.73 86.27 0.565 0.661 3.995 & 5.125Pio 1284260 7.41 92.59 0.306 0.439
Photolytic (sun light 
24 hr)
Alo 1888497 4.46 95.54 0.528 0.667
2.532 & 5.134Pio 1290513 6.96 93.04 0.315 0.444
Alo: Aloglitpin; Pio: Pioglitazone
Table 7. Summary of proposed and reported RP-HPLC methods
Drug Run time 
(min)
Linearity
(µg/mL)
LOD
(µg/mL)
LOQ
(µg/mL)
RSD
(%)
Recovery  
(%)
Reference
Alo
10
6.25-31.25 0.555 1.680 0.404-1.069 101.01-101.07
Raval & Srinivasa (12)
Pio 3.75-18.75 0.139 0.423 0.553-1.124 99.84-100.77
Alo
10
31-187 0.339 1.210 0.31 99.87-100.56
Neelima et al. (13)
Pio 75-450 0.516 1.565 0.32 99.62-100.61
Alo
8
2.5-15 0.034 0.012 0.257 98.44-100.40
Manzoor et al. (14)
Pio 3-18 0.034 0.105 0.230 99.16-100.55
Alo
6
5-100 0.170 0.500 0.23-1.10 99.12-99.48
Mokhtar et al. (15)
Pio 5-100 0.215 0.650 0.31-1.54 101.38-101.95
Alo
7
6.25-18.75 0.047 0.157 0.152 99.45-99.69
Proposed
Pio 11.25-33.75 0.085 0.284 0.236 100.18-100.42
Alo: Aloglitpin; Pio: Pioglitazone
HPLC methods. The total run time of the proposed method 
was less when compared with the reported HPLC methods 
(12-14). The less run time may decrease the utilization of 
solvents, time and cost of analysis. The proposed method has 
wider range of linearity than the Manzoor et al. (14) method. 
The validation parameters like system suitability (13) and 
specificity (12-14) is not reported in some of the reported 
HPLC methods. The volume of sample for analysis in the 
proposed method (10 µL) is lesser than the methods (20 µL) 
of Manzoor et al. (14) and Mokhtar et al. (15).
4. CONCLUSION
In the present study, an attempt was made to develop an 
accurate, precise, selective and sensitive RP-HPLC method 
for the simultaneous analysis of alogliptin and pioglitazone 
in bulk and combined tablet dosage forms. The method 
was validated in accordance with ICH guidelines. The 
main features of the developed method are economical, 
low run time, selective, robust, sensitive and satisfactory 
precision and accuracy. Therefore, the suggested RP-HPLC 
method can be used for the simultaneous quantification of 
alogliptin and pioglitazone in quality control laboratories 
or industry.
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